Ipriflavone can regulate the differentiation and biosynthesis of human bone marrow stromal progenitor cells (BMC) by enhancing the expression of some important matrix proteins and promoting the mineralization process. In the cultured undifferentiated bone cells of mice, Ipriflavone μ Treatment at dose M significantly inhibited bone resorption enhanced by advanced glycation end products (AGE).